Global Allergy Immunotherapy Market Report and Forecast 2024-2032

Global Allergy Immunotherapy Market Outlook

The global allergy immunotherapy market size attained a value of USD 2.24 billion in 2023 driven highly by increase in prevalence of allergic diseases. The market is anticipated to grow at a CAGR of 9.6% during the forecast period of 2024-2032 to attain a value of USD 5.10 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by Increase in Prevalence of Allergic Diseases

In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. Allergies can have a significant affect on health and quality of life. Allergen immunotherapy can provide long-lasting therapeutic relief to people suffering from environmental allergies. Allergen immunotherapy (also called allergy shots) refers to a type of long-term treatment that reduces symptoms for individuals experiencing allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots reduce sensitivity to allergens and usually offer lasting relief from allergy symptoms even after the treatment is stopped, making it an economical and beneficial treatment approach for several people. Immunotherapy is a preventive treatment for allergic reactions to substances like grass pollens, house dust mites and bee venom; it also decreases inflammation that characterizes rhinitis and asthma.

Adults as well as children may receive allergy shots, however, the treatment is not usually suggested for children below age five. When considering allergen immunotherapy for an older adult, medical conditions including cardiac disease must be taken into consideration. Important considerations include: duration of allergy season and severity of symptoms; how well medications and environmental controls are helping allergy symptoms; the patient’s desire to avoid long-term medication use; time available for treatment; cost. Food allergies are not treated through allergy shots.

Allergen Immunotherapy has been Shown to Reduce Symptoms of Several Allergies

Allergy shots act like a vaccine; the body responds to injected amounts of a specific allergen, administered in gradually increasing doses, by developing immunity or tolerance to the allergen. The gradual increases of the allergen enable the immune system to become less sensitive to the substance, possibly by causing production of a “blocking” antibody which decreases the symptoms of allergy when the substance is encountered in the future. In the build-up phase, injections are administered with increasing amounts of the allergens one to two times per week; the phase may last three to six months. The maintenance phase commences once the effective dose is reached; the effective dose depends on allergen sensitivity levels and the person’s response to the build-up phase. During the maintenance phase, the duration of time between shots might become longer (two to four weeks).

Allergen immunotherapy has been shown to reduce symptoms of several allergies; it may also prevent the development of new allergies. In children, it could prevent the development of allergic disease from allergic rhinitis to asthma. The relief provided by allergen immunotherapy is expected to boost the global allergy immunotherapy market.

Indications for allergen immunotherapy include moderate-to-severe allergic rhinitis; allergic asthma; allergic conjunctivitis; allergic rhino-conjunctivitis; atopic dermatitis; immune-mediated and IgE-mediated food allergy; insect allergy that causes significant local reaction and anaphylaxis.

Developments in the Domain Likely to Boost Market Growth

In 2020, it was reported that researchers from the University of Tsukuba had developed a novel system that enabled the mass production of the major birch pollen allergen Bet v 1 in plant leaves in just a few days. A study published in Frontiers in Plant Science showed that their system not only produced large amounts of Bet v 1, but the purified protein was also highly reactive towards the IgE antibodies in sera from individuals with birch pollen allergy. Such developments, along with several others in the domain, are expected to boost the global allergy immunotherapy market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

By allergy, the market is segmented into:

• Allergic Asthma
• Cat Allergy
• Allergic Rhinitis
• Peanut Allergy
• Others

By treatment, the market is divided into:

• Sublingual Immunotherapy
• Subcutaneous Immunotherapy (SCIT)
• Specific Immunotherapy (SIT)

By distribution channel, the market is classified into:

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By region, the market is segmented into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global Allergy Immunotherapy market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• ASIT Biotech
• Circassia Group PLC
• Adamis Pharmaceuticals Corporation
• Merck KGaA
• Stallergenes Greer Ltd
• Allergy Therapeutics PLC
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report